You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
TGA business plan 2014-2015
Therapeutic Goods Administration
Funding, capital expenditure and anticipated revenue
Our finances are managed through the Therapeutic Goods Special Account (under Section 80 of the Public Governance, Performance and Accountability Act 2013 and Section 45 of the Therapeutic Goods Act 1989).
TGA's activities are fully cost recovered from fees and charges imposed on industry, with the exception of Government funding provided for the alignment of Australia and New Zealand therapeutic arrangements, and departmental funding for the operation of the Drug Control Section and Medicines Scheduling Secretariat.
Portfolio budget statements
TGA Special Account
|Budgeted increase in expenditure (including capital) comprises:|
|Estimated actual 2013-14||$137,334,000|
|Budgeted expenses 2014-15 (including capital)||$147,736,000|
The increase in expenditure (including capital) in 2014-15 relates to funding provided for Government budget measures and capital funding for the Business Improvement Program.
Out year 1
Out year 2
Out year 3
|Approved internally funded projects||$15,231,000||$10,621,000||$7,710,000||$5,710,000|
Capital expenditure includes funding for the Business Improvement Program, funding for Government budget measures and standard lifecycle replacement programs for property, information technology and laboratory equipment.